Recruiting
Early Phase 1

Implantable Microdevice

Sponsor:

Oliver Jonas

Code:

NCT07892300

Conditions

Lung Cancer

Mesothelioma

Suspected Lung Cancer

Suspected Mesothelioma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Implantable Micro- drug delivery Microdevice (IMD)

Study Details

Brief summary:

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma.

The name of the intervention(s) involved in this study are:

Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.

Conditions

Lung Cancer

Mesothelioma

Suspected Lung Cancer

Suspected Mesothelioma

Study ID

NCT07892300

Start date

Nov 16, 2026

Status verified date

Nov, 2026

Completion date

Nov 30, 2031

Anticipated

Primary completion date

Nov 16, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
  • Participants must have confirmed or suspected lung cancer or mesothelioma or other intrathoracic malignancy, and are planned for surgical resection of the tumor as part of their standard clinical care.
  • Participants must be 18 years of age or older.
  • Participants must be evaluated by a medical oncologist or surgeon who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease.
  • Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures.
  • Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥120,000/mcL, Prothrombin time (PT) (International Normalized Ratio) 1.5 and Partial Thromboplastin Time (PTT) <1.5x control.
  • Participants must have undergone computed tomography (CT), magnetic resonance imaging (MRI)) or other clinical imaging that assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care.
  • The participant's case must be reviewed by representatives of interventional radiology and the appropriate surgical subspecialty to assess the following factors:

  • Patient is clinically stable to undergo microdevice implantation and surgical procedures.
  • Patient has sufficient volume of disease to allow implantation of the microdevice.
  • Patient has a lesion for which the microdevice is a) amenable to percutaneous placement, and b) amenable to removal at the time of surgery.
  • Patients must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories.

Exclusion Criteria:

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
  • Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or biopsy procedures (detailed below).

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Implantable Microdevice (IMD) + Standard-of-care Surgical Retrieval + Standard-of-Care Treatment

Participants with confirmed or suspected lung cancer or malignant mesothelioma who are candidates for standard-of-care surgical tumor resection will be eligible for study participation and will undergo the following study procedures:

  • \*\*Microdevice implantation:\*\* Placement of 1-4 investigational drug-releasing microdevices into an accessible tumor approximately 72 ± 24 hours prior to scheduled standard-of-care surgery. Microdevices may be implanted using image-guided percutaneous techniques or other clinically appropriate approaches, depending on tumor location and accessibility. The number of microdevices implanted will be determined on a case-by-case basis based on tumor characteristics, anatomical location, procedural feasibility, and participant-specific considerations.
  • \*\*Microdevice retrieval and tissue collection:\*\* At the time of scheduled standard-of-care surgery, the implanted microdevices will be surgically retrieved along with surrounding tumor tissue and analyzed.

Interventions

Implantable Micro- drug delivery Microdevice (IMD)

Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib.

Primary outcome measure

  • Safety of microdevice implantation and indwelling [ Time Frame: up to 30 days ]

Central Contacts and Locations

Central contacts

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

More Information

Sponsor

Oliver Jonas

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • non small cell lung cancer
  • small cell lung cancer
  • mesothelioma
  • suspected lung cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Oliver Jonas on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.